Clinical Takeaway
In a controlled crossover trial of healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability or sedation compared to placebo. This suggests CBD may not possess meaningful intrinsic anti-epileptic or sedative properties on its own, and its clinical benefits in seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome likely depend on its pharmacokinetic interaction with clobazam rather than direct brain effects. Patients and clinicians should understand that CBD’s effectiveness in these conditions is probably not a standalone mechanism.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may derive primarily from pharmacokinetic interactions with concurrent antiepileptic medications rather than direct effects on neuronal excitability, which has critical implications for dosing strategies and drug combination protocols. The finding that CBD lacks direct cortical effects challenges assumptions about its mechanism of action and suggests clinicians should optimize its use through careful selection of companion drugs rather than relying on inherent anticonvulsant properties. Understanding this interaction-dependent mechanism is essential for predicting efficacy in patients on different antiepileptic regimens and avoiding inappropriate monotherapy applications.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This rigorously designed crossover trial challenges a widely held assumption about cannabidiol’s mechanism of action by demonstrating that CBD lacks direct effects on cortical excitability in humans, suggesting its clinical benefit in seizure disorders may depend largely on pharmacokinetic interactions with concurrent antiepileptic medications like clobazam rather than intrinsic anticonvulsant properties. While the study’s controlled design strengthens confidence in the negative findings, important caveats include the inherent difficulty of measuring cortical excitability in healthy volunteers versus seizure-prone populations, potential differences in CBD’s effects at various doses and tissue distributions, and the possibility that indirect mechanisms not captured by standard excitability measures could still contribute clinically. The lack of observed sedative effects also warrants consideration given heterogeneous patient reports and variable study conditions. For practitioners, this research suggests that CBD’s documented efficacy in specific epilepsy syndromes may be less about standalone neuroprotection and more about how it modulates concurrent medications, under
| |